Hemoglobinopathies
Welcome,         Profile    Billing    Logout  
 43 Companies   55 Products   55 Products   60 Mechanisms of Action   1 Trial   670 News 


«12345678910111213...1314»
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  A Phase II Trial of Regadenoson in Sickle Cell Anemia (clinicaltrials.gov) -  Feb 7, 2018   
    P2,  N=100, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2017 --> May 2017 Recruiting --> Completed
  • ||||||||||  Trial completion date, Trial primary completion date:  Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease (clinicaltrials.gov) -  Feb 6, 2018   
    P1,  N=15, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2020 | Trial completion date: Jun 2017 --> Jun 2020
  • ||||||||||  Trial completion, Trial primary completion date:  Vitamin D3 in Patients With Sickle Cell Disease (clinicaltrials.gov) -  Jan 19, 2018   
    P=N/A,  N=50, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016
  • ||||||||||  NVX-508 / NuvOx Pharma
    Trial initiation date, Trial primary completion date:  A Phase Ib Study of NVX-508 in Sickle Cell Disease (clinicaltrials.gov) -  Dec 14, 2017   
    P1,  N=24, Not yet recruiting, 
    N=194 --> 87 Initiation date: Nov 2017 --> Feb 2018 | Trial primary completion date: May 2018 --> Aug 2018
  • ||||||||||  Trial completion, Phase classification, Immunomodulating:  the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children (clinicaltrials.gov) -  Oct 25, 2017   
    P=N/A,  N=60, Completed, 
    Recruiting --> Active, not recruiting | N=134 --> 91 | Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A
  • ||||||||||  Campath (alemtuzumab) / Sanofi
    Trial completion:  Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia (clinicaltrials.gov) -  Oct 20, 2017   
    P2,  N=21, Completed, 
    Active, not recruiting --> Completed | Phase classification: P4 --> PN/A Active, not recruiting --> Completed
  • ||||||||||  hydroxyurea / Generic mfg.
    Enrollment change, Trial withdrawal:  Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study (clinicaltrials.gov) -  Oct 17, 2017   
    P2,  N=0, Withdrawn, 
    Active, not recruiting --> Completed N=10 --> 0 | Terminated --> Withdrawn
  • ||||||||||  hydroxyurea / Generic mfg.
    Trial completion, Trial primary completion date:  Hydroxyurea in the Treatment of Sickle Cell Disease (clinicaltrials.gov) -  Oct 6, 2017   
    P=N/A,  N=628, Completed, 
    Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Nov 2016
  • ||||||||||  Trial completion:  Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease (clinicaltrials.gov) -  Oct 6, 2017   
    P=N/A,  N=80, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Nov 2016 Active, not recruiting --> Completed
  • ||||||||||  NVX-508 / NuvOx Pharma
    Trial primary completion date:  A Phase Ib Study of NVX-508 in Sickle Cell Disease (clinicaltrials.gov) -  Oct 5, 2017   
    P1,  N=24, Not yet recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> May 2018
  • ||||||||||  montelukast / Generic mfg.
    P2 data, Trial primary completion date:  Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (clinicaltrials.gov) -  Aug 17, 2017   
    P2,  N=63, Recruiting, 
    No longer recruiting --> Completed Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  Trial completion, Enrollment change:  Genetic Factors Affecting the Severity of Beta Thalassemia (clinicaltrials.gov) -  Aug 10, 2017   
    P=N/A,  N=50, Completed, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Completed | N=200 --> 50
  • ||||||||||  hydroxyurea / Generic mfg.
    Trial completion:  Evaluating Thromboelastography (TEG) and ETP in Sickle Adults (clinicaltrials.gov) -  Aug 1, 2017   
    P=N/A,  N=100, Completed, 
    Recruiting --> Completed | N=13 --> 9 | Trial primary completion date: Apr 2018 --> Mar 2017 Not yet recruiting --> Completed
  • ||||||||||  NVX-508 / NuvOx Pharma
    Trial initiation date:  A Phase Ib Study of NVX-508 in Sickle Cell Disease (clinicaltrials.gov) -  Jul 25, 2017   
    P1,  N=24, Not yet recruiting, 
    Not yet recruiting --> Completed Initiation date: Jun 2017 --> Sep 2017
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Trial termination:  Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease (clinicaltrials.gov) -  Jul 21, 2017   
    P2,  N=5, Terminated, 
    Initiation date: Jun 2017 --> Sep 2017 Completed --> Terminated; The study terminated early due to slow accrual.
  • ||||||||||  Trial completion:  Heart Disease in Sickle Cell Anemia (clinicaltrials.gov) -  Jun 30, 2017   
    P=N/A,  N=120, Completed, 
    Completed --> Terminated; The study terminated early due to slow accrual. Recruiting --> Completed
  • ||||||||||  propranolol ER / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease (clinicaltrials.gov) -  Jun 8, 2017   
    P1,  N=9, Terminated, 
    Not yet recruiting --> Recruiting N=20 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2012; Inability to recruit patients into the study.
  • ||||||||||  Amevive (alefacept) / Astellas
    Trial termination:  Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Jun 7, 2017   
    P=N/A,  N=3, Terminated, 
    N=20 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Nov 2012; Inability to recruit patients into the study. Suspended --> Terminated; drug company is no longer making the drug
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial completion, Enrollment change, Trial primary completion date:  Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease (clinicaltrials.gov) -  May 15, 2017   
    P2,  N=22, Completed, 
    Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Active, not recruiting --> Completed | N=15 --> 22 | Trial primary completion date: Dec 2017 --> Jun 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease (clinicaltrials.gov) -  May 3, 2017   
    P=N/A,  N=28, Completed, 
    Active, not recruiting --> Completed | N=15 --> 22 | Trial primary completion date: Dec 2017 --> Jun 2016 Recruiting --> Completed | N=40 --> 28 | Trial primary completion date: Dec 2016 --> Dec 2015
  • ||||||||||  Phase classification, Trial primary completion date:  Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C (clinicaltrials.gov) -  Apr 28, 2017   
    P=N/A,  N=60, Active, not recruiting, 
    Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Phase classification, Trial primary completion date:  Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major (clinicaltrials.gov) -  Apr 28, 2017   
    P=N/A,  N=60, Active, not recruiting, 
    Phase classification: P4 --> P=N/A | Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P4 --> P=N/A | Trial primary completion date: Mar 2017 --> Oct 2017
  • ||||||||||  Trial completion, Trial primary completion date:  MBSR for Pain Catastrophizing in SCD (clinicaltrials.gov) -  Apr 26, 2017   
    P=N/A,  N=60, Completed, 
    Phase classification: P4 --> P=N/A | Trial primary completion date: Mar 2017 --> Oct 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016